Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: A systemic review and meta-analysis

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1649-1652

  Wang, Lichun ^a   Liu, Zehan ^a   Jing, Pengwei ^b   Shao, Lin ^a   Chen, Lin ^a   He, Xu ^a   Gong, Weixun ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

MDM2; Meta analysis; Osteosarcoma; Polymorphism

Indexed keywords

PROTEIN MDM2;

CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CODOMINANCE; DNA POLYMORPHISM; DOMINANT GENE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; META ANALYSIS (TOPIC); OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RECESSIVE GENE; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; BONE NEOPLASMS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; OSTEOSARCOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84898786185     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1227-8     Document Type: Review

References (20)

1. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247-63.
2. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:vii320-5.
3. Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:137-9.
4. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-9. (Pubitemid 27220766)
5. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299-303. (Pubitemid 27220767)
6. Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137:609-22.
7. van der Deen M, Taipaleenmaki H, Zhang Y, Teplyuk NM, Gupta A, Cinghu S, et al. MicroRNA-34c inversely couples the biological functions of the Runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem. 2013;288:21307-19.
8. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis. 2007;28:2262-7. (Pubitemid 350119563)
9. Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, et al. Effect of TP53 Arg72pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15:3550-6.
10. Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res. 2011;17:416-26.
11. Mirabello L, Yu K, Berndt SI, Burdett L, Wang Z, Chowdhury S, et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer. 2011;11:209.
12. Naumov VA, Generozov EV, Solovyov YN, Aliev MD, Kushlinsky NE. Association of FGFR3 and MDM2 gene nucleotide polymorphisms with bone tumors. Bull Exp Biol Med. 2012;153:869-73.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. (Pubitemid 37088507)
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. (Pubitemid 17189972)
15. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
16. Iwakuma T, Agarwal N. MDM2 binding protein, a novel metastasis suppressor. Cancer Metastasis Rev. 2012;31:633-40.
17. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83-96.
18. Miliani de Marval PL, Zhang Y. The RP-MDM2-p53 pathway and tumorigenesis. Oncotarget. 2011;2:234-8.
19. Walker CW, Van Beneden RJ, Muttray AF, Bottger SA, Kelley ML, Tucker AE, et al. P53 superfamily proteins in marine bivalve cancer and stress biology. Adv Mar Biol. 2011;59:1-36.
20. Kamal A, Mohammed AA, Shaik TB. P53-MDM2 inhibitors: patent review (2009-2010). Expert Opin Ther Pat. 2012;22:95-105.